# Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

> **NCT02187991** · PHASE2 · COMPLETED · sponsor: **US Oncology Research** · enrollment: 169 (actual)

## Conditions studied

- Breast Cancer
- Breast Carcinoma
- Breast Tumors
- Malignant Neoplasm of Breast

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT02187991
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-12
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-08-01
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187991, "Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02187991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*